Abstract
Aim This is the first review to summarize the population pharmacokinetic
studies of oxcarbazepine and explored the significant covariates that
may have an impact on the dosage regimen and clinical use of
oxcarbazepine. Methods PubMed and Embase databases were searched before
31 October 2020, and references of all selected studies were further
screened to identify the pertinent population pharmacokinetic studies of
oxcarbazepine. Relevant information about the identified population
pharmacokinetic studies was summarised, and the quality of the reports
was evaluated. Moreover, studies among infant, children, and adult
patients were compared. Results Twelve studies were included: seven
studies enrolled paediatric patients only; two enrolled both paediatric
and adult patients; and two enrolled adult patients only. The apparent
clearance per weight for children (median: 0.0505 L/h/kg, range:
0.016-0.084) and infants (0.078 L/h/kg) were higher than that for adults
(median: 0.036 L/h/kg, range: 0.029-0.06). Furthermore, children had a
larger variation on clearance compared to adults. Weight,
co-administration with enzyme-inducing antiepileptic drugs, and renal
function were found to significantly affect clearance of
10-hydroxycarbazepine. Conclusion The oxcarbazepine dose regimen was
dependent on weight, co-administration with enzyme-inducing medications,
and renal function. Further study is essential to explore the
pharmacodynamics in epilepsy patients and pharmacokinetics of
oxcarbazepine in infants.